Mersana Therapeutics
Platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $100m | Post IPO Debt |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (98 %) | (95 %) | 61716 % | 39 % | 10 % | (45 %) | 84 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (10468 %) | (392693 %) | (767 %) | (427 %) | (156 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (10633 %) | (395488 %) | (768 %) | (466 %) | (171 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 8096 % | 307007 % | 652 % | 402 % | 180 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Mersana Therapeutics is a biopharmaceutical company focused on discovering and developing innovative antibody-drug conjugates (ADCs) to treat cancer. The company leverages its proprietary technology platforms, Dolasynthen and Immunosynthen, to create a robust pipeline of ADCs designed to target and destroy cancer cells while sparing healthy tissue. Mersana operates in the oncology market, serving patients and healthcare providers who seek advanced treatment options for various types of cancer. The company's business model involves research and development, clinical trials, and partnerships with other pharmaceutical companies to bring its ADCs to market. Revenue is generated through public offerings, partnerships, and potential future sales of approved therapies. Mersana's multiprong strategy includes both cytotoxic and immunostimulatory ADCs, aiming to provide comprehensive solutions for cancer treatment.
Keywords: biopharmaceutical, oncology, antibody-drug conjugates, cancer treatment, Dolasynthen, Immunosynthen, clinical trials, innovation, healthcare, partnerships.